IDEXX Laboratories Company Insiders

IDXX Stock  USD 418.55  0.06  0.01%   
IDEXX Laboratories' insiders are aggressively selling. The analysis of insiders' sentiment of trading IDEXX Laboratories stock suggests that vertually all insiders are panicking at this time. IDEXX Laboratories employs about 11 K people. The company is managed by 15 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 733.33 employees per reported executive.
Michael Lane  President
Corporate Vice President General Manager
Sharon Underberg  President
Corporate Vice President General Counsel, and Corporate Secretary

IDEXX Laboratories' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-05-17Bruce L ClaflinDisposed 200 @ 540.8View
2024-02-08George FennellDisposed 8198 @ 573.87View
2024-02-07Jonathan Jay MazelskyDisposed 12000 @ 572.61View
2024-01-22Tommy TubervilleDisposed @ 531.43
2023-12-07James F PolewaczykDisposed 11636 @ 521.79View
2023-12-04Jonathan Jay MazelskyDisposed 7128 @ 513.05View
Monitoring IDEXX Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

IDEXX Laboratories' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with IDEXX Laboratories' future performance. Based on our forecasts, it is anticipated that IDEXX will maintain a workforce of slightly above 11000 employees by December 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

IDEXX Laboratories' latest congressional trading

Congressional trading in companies like IDEXX Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in IDEXX Laboratories by those in governmental positions are based on the same information available to the general public.
2024-02-14Senator Tommy TubervilleAcquired Under $15KVerify
2024-02-13Senator Tommy TubervilleAcquired Under $15KVerify

IDEXX Laboratories Management Team Effectiveness

The company has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.
Common Stock Shares Outstanding is likely to rise to about 94.9 M in 2024. Net Income Applicable To Common Shares is likely to rise to about 820 M in 2024

IDEXX Laboratories Workforce Comparison

IDEXX Laboratories is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 408,459. IDEXX Laboratories holds roughly 11,000 in number of employees claiming about 2.69% of equities under Health Care industry.

IDEXX Laboratories Profit Margins

The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.37 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.37.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.610.5982
Fairly Up
Slightly volatile
Net Profit Margin0.240.2308
Sufficiently Up
Slightly volatile
Operating Profit Margin0.310.2997
Sufficiently Up
Slightly volatile
Pretax Profit Margin0.30.2899
Sufficiently Up
Slightly volatile
Return On Assets0.270.2592
Sufficiently Up
Slightly volatile

IDEXX Laboratories Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IDEXX Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on IDEXX Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IDEXX Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.5
2
4
 576.00 
 863.00 
2024-06-01
3.4444
31
9
 11,078 
 2,032 
2024-03-01
0.6642
89
134
 142,692 
 233,465 
2023-12-01
0.4375
7
16
 26,807 
 54,826 
2023-09-01
0.5517
16
29
 195,491 
 250,420 
2023-06-01
0.8095
34
42
 24,953 
 62,208 
2023-03-01
1.1833
71
60
 112,250 
 56,054 
2022-12-01
0.2857
8
28
 64,941 
 114,086 
2022-09-01
0.7143
5
7
 450,612 
 455,852 
2022-06-01
3.375
27
8
 16,783 
 2,610 
2022-03-01
1.3333
76
57
 109,530 
 29,526 
2021-12-01
0.3214
9
28
 49,092 
 99,146 
2021-09-01
0.3582
24
67
 36,716 
 78,413 
2021-06-01
0.7436
29
39
 48,528 
 109,096 
2021-03-01
1.012
84
83
 172,760 
 139,542 
2020-12-01
0.1008
12
119
 61,167 
 260,816 
2020-09-01
0.3793
22
58
 207,426 
 443,703 
2020-06-01
0.9189
34
37
 128,990 
 292,419 
2020-03-01
0.4812
64
133
 191,946 
 320,807 
2019-12-01
0.5455
12
22
 107,422 
 248,815 
2019-09-01
0.75
27
36
 112,012 
 159,916 
2019-06-01
1.1053
21
19
 57,765 
 95,599 
2019-03-01
0.825
66
80
 248,124 
 182,324 
2018-12-01
1.0
6
6
 8,790 
 43,728 
2018-09-01
0.7143
25
35
 173,448 
 244,035 
2018-06-01
0.6452
20
31
 18,847 
 139,394 
2018-03-01
0.7778
49
63
 283,378 
 267,779 
2017-12-01
0.2121
7
33
 49,725 
 231,932 
2017-09-01
0.6897
20
29
 128,414 
 236,196 
2017-06-01
1.3333
24
18
 135,117 
 213,874 
2017-03-01
1.0238
43
42
 315,068 
 228,188 
2016-12-01
0.4
12
30
 86,515 
 259,765 
2016-09-01
0.5789
11
19
 180,213 
 325,435 
2016-06-01
4.2
21
5
 70,724 
 24,851 
2016-03-01
1.25
50
40
 473,799 
 72,298 
2015-12-01
0.7273
8
11
 39,442 
 49,642 
2015-09-01
0.7647
13
17
 58,579 
 88,023 
2015-06-01
2.4444
22
9
 57,016 
 31,676 
2015-03-01
0.8852
54
61
 286,385 
 245,302 
2014-12-01
0.5652
13
23
 90,433 
 163,636 
2014-09-01
1.4
14
10
 48,740 
 43,162 
2014-06-01
2.4444
22
9
 34,909 
 14,430 
2014-03-01
1.2162
45
37
 255,611 
 202,219 
2013-12-01
0.8421
32
38
 362,910 
 530,970 
2013-09-01
0.8571
6
7
 25,442 
 40,134 
2013-06-01
1.5333
23
15
 72,806 
 40,328 
2013-03-01
0.9714
102
105
 429,536 
 572,563 
2012-12-01
0.42
21
50
 177,995 
 394,152 
2012-09-01
0.6
27
45
 141,810 
 239,572 
2012-06-01
1.1818
26
22
 82,212 
 111,342 
2012-03-01
1.4615
76
52
 238,745 
 99,586 
2011-12-01
0.4091
9
22
 92,899 
 154,958 
2011-09-01
0.6316
12
19
 115,509 
 202,241 
2011-06-01
0.9394
31
33
 225,109 
 289,654 
2011-03-01
1.3118
122
93
 667,530 
 472,107 
2010-12-01
0.75
9
12
 185,302 
 283,049 
2010-09-01
0.875
14
16
 223,305 
 366,914 
2010-06-01
0.7826
18
23
 220,244 
 362,406 
2010-03-01
1.4918
91
61
 454,974 
 274,756 
2009-12-01
0.6667
8
12
 24,793 
 47,916 
2009-09-01
0.7857
22
28
 116,420 
 201,139 
2009-06-01
1.0
10
10
 19,718 
 47,406 
2009-03-01
2.3125
74
32
 339,129 
 14,118 
2008-12-01
2.75
11
4
 68,554 
 17,424 
2008-09-01
0.8077
21
26
 137,388 
 229,987 
2008-03-01
0.8977
79
88
 321,518 
 98,794 
2007-12-01
0.6667
8
12
 66,199 
 128,992 
2007-09-01
0.7391
17
23
 47,159 
 84,078 
2007-06-01
1.0909
12
11
 28,870 
 36,421 
2007-03-01
1.617
76
47
 340,413 
 212,926 
2006-12-01
2.3333
7
3
 6,990 
 6,450 
2006-09-01
0.3
9
30
 21,081 
 105,678 
2006-06-01
3.5
7
2
 8,955 
 8,400 
2006-03-01
2.52
63
25
 167,223 
 91,151 
2005-12-01
1.0667
16
15
 42,075 
 60,962 
2005-09-01
0.625
15
24
 41,270 
 86,587 
2005-06-01
1.6667
25
15
 79,016 
 86,420 
2005-03-01
5.1667
31
6
 156,127 
 18,206 
2004-12-01
0.9286
13
14
 10,626 
 22,341 
2004-09-01
3.6667
11
3
 20,402 
 6,415 
2004-06-01
1.8
9
5
 26,300 
 16,000 
2004-03-01
1.28
32
25
 167,602 
 79,262 
2003-12-01
0.9286
26
28
 55,491 
 80,433 
2003-09-01
14.0
14
1
 118,272 
 3,500 
2003-06-01
1.0
5
5
 20,000 
 74,300 

IDEXX Laboratories Notable Stakeholders

An IDEXX Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IDEXX Laboratories often face trade-offs trying to please all of them. IDEXX Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IDEXX Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jonathan MazelskyCEO PresidentProfile
Michael LaneCorporate Vice President General ManagerProfile
Sharon UnderbergCorporate Vice President General Counsel, and Corporate SecretaryProfile
Brian McKeonCFO, Principal Accounting Officer, Executive VP and TreasurerProfile
Nimrata PESector StrategyProfile
Martin SmithExecutive CTOProfile
Sharon JDGeneral VPProfile
Jeffery ChadbourneDirector ReportingProfile
George FennellSenior OfficerProfile
Ken GradySenior OfficerProfile
Kerry BennettSenior LabsProfile
Michael JohnsonExecutive OfficerProfile
James PolewaczykExecutive OfficerProfile
John HartSenior OperationsProfile
Michael EricksonExecutive TelemedicineProfile

About IDEXX Laboratories Management Performance

The success or failure of an entity such as IDEXX Laboratories often depends on how effective the management is. IDEXX Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IDEXX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IDEXX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.30  0.32 
Return On Capital Employed 0.48  0.26 
Return On Assets 0.26  0.27 
Return On Equity 0.57  0.60 
Please note, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Check IDEXX Laboratories' Beneish M Score to see the likelihood of IDEXX Laboratories' management manipulating its earnings.

IDEXX Laboratories Workforce Analysis

Traditionally, organizations such as IDEXX Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IDEXX Laboratories within its industry.

IDEXX Laboratories Manpower Efficiency

Return on IDEXX Laboratories Manpower

Revenue Per Employee332.8K
Revenue Per Executive244.1M
Net Income Per Employee76.8K
Net Income Per Executive56.3M
Working Capital Per Employee49.4K
Working Capital Per Executive36.2M

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.